Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 82,248	$ 124,775
Short-term investments	0	42,086
Accounts receivable	48,494	33,729
Inventories, net	65,623	35,201
Prepaid clinical development costs	193	1,026
Other prepaid and current assets	4,507	9,866
Total current assets	201,065	246,683
Noncurrent assets:
Property and equipment, net	0	164
Right of use operating lease assets	4,675	1,036
Intangible assets	56	56
Total assets	205,796	247,939
Current liabilities:
Accounts payable	31,718	23,040
Accrued clinical development costs	3,441	5,426
Accrued legal fees	34,284	21,987
Other accrued liabilities	24,998	13,204
Revenue interest liability	34,828	24,760
Deferred revenue from collaborations	25,402	3,507
Operating lease liabilities	1,553	384
Total current liabilities	156,224	92,308
Convertible notes, net of issuance costs	261,596	259,899
Revenue interest liability	239,950	218,845
Operating lease liabilities	3,020	665
Total liabilities	660,790	571,717
Commitments and contingencies (Note 5)
Stockholders’ (deficit) equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of December 31, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value; 480,000,000 shares authorized as of December 31, 2023 and 240,000,000 shares authorized as of December 31, 2022; 120,204,513 shares issued at December 31, 2023 and 76,564,396 shares issued at December 31, 2022	118	75
Additional paid-in capital	1,149,170	1,071,183
Treasury stock, at cost; 1,994,198 shares at December 31, 2023 and December 31, 2022	(54,998)	(54,998)
Accumulated other comprehensive loss	0	(2)
Accumulated deficit	(1,549,284)	(1,340,036)
Total stockholders' deficit	(454,994)	(323,778)
Total liabilities and stockholders' deficit	$ 205,796	$ 247,939